<DOC>
	<DOCNO>NCT00510445</DOCNO>
	<brief_summary>The purpose study determine safety maximum tolerate dose ( MTD ) GRN163L administer combination standard paclitaxel/carboplatin regimen patient advance metastatic non-small cell lung cancer .</brief_summary>
	<brief_title>Study GRN163L With Paclitaxel Carboplatin Patients With Advanced Metastatic Non Small Cell Lung Cancer</brief_title>
	<detailed_description>GRN163L telomerase template antagonist vitro vivo activity variety tumor model system . Telomerase enzyme active primarily tumor cell crucial indefinite growth tumor cell . Inhibition telomerase may result antineoplastic effect .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis NSCLC Stage IIIb pleural effusion , Stage IV , recurrent disease Measurable evaluable disease RECIST criterion ECOG performance status 01 Adequate hepatic/renal function platelet count If previously treat anthracycline , anthracenedione , trastuzumab , must leave ventricular ejection fraction &gt; 50 % More 2 prior chemotherapy regimens metastatic disease ( prior adjuvant chemotherapy allow ) Tumor progression treatment paclitaxel ( refractory paclitaxel ) Taxanebased regimen within 12 week Any systemic therapy cancer within 4 week Antiplatelet therapy within 2 week , low dose aspirin prophylaxis therapy Therapeutic anticoagulation therapy except low dose warfarin ( eg , 1 mg mouth per day ) Radiation therapy within 3 week Major surgery within 4 week ( central line placement allow ) Prolongation PT aPTT &gt; ULN fibrinogen &lt; LLN History active central nervous system metastatic disease Any active malignancy Active chronically recurrent bleeding ( eg , active peptic ulcer disease ) Clinically significant infection Active autoimmune disease require immunosuppressive therapy Clinically significant cardiovascular disease condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>Advanced Non Small Cell Lung Cancer</keyword>
	<keyword>Metastatic Non Small Cell Lung Cancer</keyword>
</DOC>